Breakpoints

124 Folgen

1. #44 – The VaxScene, a review of the COVID-19 vaccine landscape in the US with a focus on equitable distribution and vaccine hesitancy

   Vom: 17.9.2021
2. #43 – Level Up: Implementation of Beta-lactam Therapeutic Drug Monitoring

   Vom: 27.8.2021
3. #42 – The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring

   Vom: 20.8.2021
4. #41 – The Gray Zone: Antimicrobial Stewardship in Immunocompromised Hosts

   Vom: 16.7.2021
5. #40 – Breakpoints Talks Breakpoints: Microbiology Labs and Stewardship

   Vom: 18.6.2021
6. #39 – A Little More on the Littles: What Adults Should Know about ID Pediatrics

   Vom: 21.5.2021
7. #38 – You're KID-ding! Myths in ID Pediatrics

   Vom: 23.4.2021
8. #37 – A Gab about Cab: The Short on Long-Acting Antiretrovirals for HIV

   Vom: 16.4.2021
9. #36 – Monoclonal Antibodies: Gateway Drugs for Future Care Delivery Models

   Vom: 26.3.2021
10. #35 – Oral Beta-Lactams, Are We Serious?

    Vom: 19.3.2021
11. #34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

    Vom: 19.2.2021
12. #33 – A Lung Time Coming: Controversies in Community Acquired Pneumonia

    Vom: 15.1.2021
13. #32 – Unsolicited Advice: An Honest Discussion of Burnout in Stewardship

    Vom: 18.12.2020
14. #31 – “Mind the Gap”: Antimicrobial Stewardship at Transitions of Care

    Vom: 20.11.2020
15. #30 – Is More Better? The Role of Combination Therapy for MRSA

    Vom: 9.10.2020
16. #29 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

    Vom: 11.9.2020
17. #28 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

    Vom: 4.9.2020
18. #27 – Expert Updates in Gram Negative Resistance: Q&A Session

    Vom: 31.7.2020
19. #26 – OPAT - The Final Frontier, Part 2

    Vom: 19.6.2020
20. #25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

    Vom: 18.6.2020